2026-08435NoticeWallet

FDA Greenlights Ozempic Generics: Safe or Just Bureaucratic Assurance?

Published Date: 4/30/2026

Notice

Summary

The FDA has decided that OZEMPIC (semaglutide) 2 mg/1.5 mL wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep applying to sell their versions, and the FDA will keep approving them if they meet the rules. Patients and pharmacies can feel confident that OZEMPIC remains a safe and effective option.

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

Generics May Continue Seeking Approval

The FDA determined that OZEMPIC (semaglutide) 2 mg/1.5 mL was not withdrawn from sale for reasons of safety or effectiveness, so generic applicants may continue to submit abbreviated new drug applications (ANDAs) that refer to this product and the FDA will continue to approve such ANDAs if they meet legal and regulatory requirements.

Patients and Pharmacies Reassured on OZEMPIC

If you take or dispense OZEMPIC (semaglutide) 2 mg/1.5 mL, the FDA has determined it was not withdrawn for reasons of safety or effectiveness, and the product will remain listed in the Orange Book's Discontinued Drug Product List while ANDAs referring to it may be approved if they meet requirements.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
4/30/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register